Clinical Trial Update: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b [Phase 1, Phase 2]

View source ↗

Summary

First-in-human study of XMT-1536 in cancers likely to express NaPi2b, including platinum-resistant ovarian cancer and metastatic non-small cell lung cancer, ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer Metastatic
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• XMT-1536

Snippet

Sponsor: Mersana Therapeutics | Conditions: Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING